Introduction:

Oral mucositis (OM) as adverse event of chemotherapy often interfere with food intake and result in weight loss and worsen quality of life. Oral cooling system（Cooral®　BrainCool AB）is a new device that is to reduce the temperature of the mouth. We aimed to evaluate the feasibility of oral cooling system for oral mucositis in patients receiving chemotherapy.



Methods:
Eligible patients had solid tumor and received alkylating agents, platinum, anthracycline, antimetabolite, or taxanes for out patients. All patients provided written informed consent before enrollment. Cooling begins 30 minutes before the start of chemotherapy. Cooling continues until 30 minutes after the termination of the cytostatic infusion. During treatment the patient may if necessary take out the component and replace it again, for a maximum of 10 minutes. Following each cooling session a questionnaire, specifically developed for the study to assess feasibility, was completed. Primary endpoint is feasibility.

Results:
A total of 6 patients were enrolled. Median age is 55.5 (range 52-71). All of those completed the full cooling time. Two patients extended time of taking out for failure of the machine. Three patients felt poor fit of mouthpiece and saliva. One patient felt numb, although no patient was cool. One patient made OM of grade1 on day2 due to mouthpiece. It healed next day.Two patients did not develop in a taste disorder and gingivitis that developed before.

Conclusions:
Oral cooling system is well tolerated. The next step will be to evaluate oral cooling system in a randomized clinical to establish its efficacy of preventing OM.

FEASIBILITY STUDY OF ORAL COOLING SYSTEM（COORAL®） FOR ORAL MUCOSITIS IN PATIENTS RECEIVING CHEMOTHERAPY